CymaBay Therapeutics (NASDAQ: CBAY)
Some price data may be temporarily unavailable.
CymaBay Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CymaBay Therapeutics Company Info
CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
News & Analysis
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today
It became increasingly likely that seladelpar will ultimately gain regulatory approval.
Why CymaBay Therapeutics Stock Is Sinking This Week
The stock has given up some of its gains but remains up more than 130% year to date.
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
The company is about to reap more money than previously expected from a new capital-raising effort.
Why CymaBay Therapeutics Stock Popped Again Today
Days after it reported highly encouraging news from a clinical trial, the company announced a new round of capital-raising.
Why CymaBay Therapeutics Stock Is Jumping Today
The momentum continues after CymaBay reported great clinical results on Thursday.
Why Shares of CymaBay Therapeutics Are Soaring Friday
A competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy.
Why CymaBay Therapeutics Stock Nose-Dived This Week
Investors did not warmly greet the latest news from the biotech.
Here's Why CymaBay Therapeutics Rose 109% in May
The development-stage company might be able to resume the development of its lead drug candidate, which was halted in late 2019.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.